Ancrod
drugOn this page
Also known as Acc-cArvinArwinEc 3.4.21.74Protein c activatorProteinaseagkistrodon serineVenombin-aViprinex
Summary
Ancrod (CHEMBL2108481) is a phase-3 clinical-stage unknown (ATC B01AD09); indicated across 1 condition including thrombotic disease.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- ATC class: B01AD09
- Indications: 1 condition
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108481 |
| Name | Ancrod |
| Type | Unknown |
| Max phase | 3 |
| ATC | B01AD09 |
Also known as: Acc-c, Ancrod, Arvin, Arwin, Ec 3.4.21.74, Protein c activator, Proteinase, agkistrodon serine, Venombin-a, Viprinex, ANCROD
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| thrombotic disease | 3 | MONDO:0000831 | HP:0004419 |
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 3 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00141011 | PHASE3 | TERMINATED | Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke |
| NCT00300196 | PHASE3 | TERMINATED | ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke |
| NCT00343174 | PHASE3 | COMPLETED | Intravenous Ancrod for the Treatment of Acute Ischemic Stroke Within 6 Hours After Onset of Symptoms |
| NCT01621256 | PHASE1/PHASE2 | COMPLETED | Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: thrombotic disease